Proteasome inhibitor

Overview
Proteasome inhibitors are drugs that block the action of proteasomes, cellular complexes that break down proteins, like the p53 protein. Proteasome inhibitors are being studied in the treatment of cancer. In 2003, bortezomib was the first proteasome inhibitor to be approved for use in the U.S.

A derivative of epigallocatechin-3-gallate has been proposed as another proteasome inhibitor.